Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JANX NASDAQ:RCKT NYSE:RCUS NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$24.00+3.0%$23.84$21.73▼$71.71$1.44B2.82757,680 shs824,135 shsRCKTRocket Pharmaceuticals$3.15-1.9%$3.19$2.19▼$18.89$339.90M0.62.18 million shs2.63 million shsRCUSArcus Biosciences$13.35-0.2%$11.03$6.50▼$18.98$1.42B0.77865,292 shs1.37 million shsSNDXSyndax Pharmaceuticals$15.60+1.0%$14.61$8.58▼$22.50$1.34B0.681.95 million shs1.77 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics0.00%+3.31%+0.25%-2.20%-44.76%RCKTRocket Pharmaceuticals0.00%-3.37%-2.48%+8.77%-81.43%RCUSArcus Biosciences0.00%+4.05%+15.33%+57.65%-13.34%SNDXSyndax Pharmaceuticals0.00%-0.51%-3.64%+68.18%-19.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$24.00+3.0%$23.84$21.73▼$71.71$1.44B2.82757,680 shs824,135 shsRCKTRocket Pharmaceuticals$3.15-1.9%$3.19$2.19▼$18.89$339.90M0.62.18 million shs2.63 million shsRCUSArcus Biosciences$13.35-0.2%$11.03$6.50▼$18.98$1.42B0.77865,292 shs1.37 million shsSNDXSyndax Pharmaceuticals$15.60+1.0%$14.61$8.58▼$22.50$1.34B0.681.95 million shs1.77 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics0.00%+3.31%+0.25%-2.20%-44.76%RCKTRocket Pharmaceuticals0.00%-3.37%-2.48%+8.77%-81.43%RCUSArcus Biosciences0.00%+4.05%+15.33%+57.65%-13.34%SNDXSyndax Pharmaceuticals0.00%-0.51%-3.64%+68.18%-19.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJANXJanux Therapeutics 2.94Moderate Buy$78.31226.28% UpsideRCKTRocket Pharmaceuticals 2.33Hold$16.67429.10% UpsideRCUSArcus Biosciences 2.50Moderate Buy$21.1458.43% UpsideSNDXSyndax Pharmaceuticals 2.82Moderate Buy$39.22151.42% UpsideCurrent Analyst Ratings BreakdownLatest RCKT, JANX, RCUS, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/3/2025RCKTRocket PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$9.00 ➝ $7.009/27/2025JANXJanux TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025RCKTRocket PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RCUSArcus BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/17/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/16/2025JANXJanux TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$47.009/10/2025JANXJanux TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.009/10/2025JANXJanux TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJANXJanux Therapeutics$10.59M136.18N/AN/A$19.49 per share1.23RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/ARCUSArcus Biosciences$258M5.51N/AN/A$5.30 per share2.52SNDXSyndax Pharmaceuticals$23.68M56.75N/AN/A$3.38 per share4.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest RCKT, JANX, RCUS, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJANXJanux TherapeuticsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJANXJanux TherapeuticsN/A47.0347.03RCKTRocket Pharmaceuticals0.056.396.39RCUSArcus Biosciences0.184.504.50SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJANXJanux Therapeutics75.39%RCKTRocket Pharmaceuticals98.39%RCUSArcus Biosciences92.89%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipJANXJanux Therapeutics8.10%RCKTRocket Pharmaceuticals24.76%RCUSArcus Biosciences9.60%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJANXJanux Therapeutics3060.09 million55.23 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableRCKT, JANX, RCUS, and SNDX HeadlinesRecent News About These CompaniesSyndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA DecisionOctober 4 at 12:17 AM | msn.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 3 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $39.22 Average Target Price from BrokeragesOctober 2 at 2:43 AM | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 29, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG ResearchSeptember 20, 2025 | marketbeat.comSyndax announces updated NCCN Guidelines for AMLSeptember 19, 2025 | msn.comSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...September 19, 2025 | finance.yahoo.comSyndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaSeptember 19, 2025 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8% - Time to Sell?September 17, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Stifel NicolausSeptember 12, 2025 | marketbeat.comZimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDXSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comInsider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 157,307 Shares of StockSeptember 10, 2025 | marketbeat.comSyndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeptember 10, 2025 | seekingalpha.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Purchases 21,630 Shares of Syndax Pharmaceuticals, Inc. $SNDXSeptember 9, 2025 | marketbeat.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.76 Million Stake in Syndax Pharmaceuticals, Inc. $SNDXSeptember 7, 2025 | marketbeat.comGuggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)September 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCKT, JANX, RCUS, and SNDX Company DescriptionsJanux Therapeutics NASDAQ:JANX$24.00 +0.69 (+2.96%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$24.24 +0.25 (+1.02%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Rocket Pharmaceuticals NASDAQ:RCKT$3.15 -0.06 (-1.87%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.18 +0.04 (+1.11%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Arcus Biosciences NYSE:RCUS$13.34 -0.03 (-0.19%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$13.67 +0.32 (+2.44%) As of 10/3/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Syndax Pharmaceuticals NASDAQ:SNDX$15.60 +0.16 (+1.04%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.52 -0.08 (-0.54%) As of 10/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
